ImageneBio (NASDAQ:IMA) Now Covered by Leerink Partners

Equities research analysts at Leerink Partners assumed coverage on shares of ImageneBio (NASDAQ:IMA) in a report issued on Friday,Benzinga reports. The brokerage set an “outperform” rating and a $30.00 price target on the stock. Leerink Partners’ price objective would suggest a potential upside of 305.95% from the stock’s previous close.

Several other brokerages also recently issued reports on IMA. Wall Street Zen raised shares of ImageneBio to a “hold” rating in a research report on Friday, September 26th. Zacks Research downgraded shares of ImageneBio from a “strong-buy” rating to a “hold” rating in a research report on Monday, September 29th. Weiss Ratings began coverage on shares of ImageneBio in a research report on Wednesday. They issued a “sell (e-)” rating for the company. Finally, Wedbush lowered their price objective on shares of ImageneBio from $25.00 to $23.00 and set a “neutral” rating for the company in a research report on Friday, July 25th. Two analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $33.67.

ImageneBio Stock Up 1.4%

Shares of NASDAQ:IMA opened at $7.39 on Friday. ImageneBio has a 52-week low of $7.24 and a 52-week high of $23.28. The company has a 50 day moving average of $9.78 and a two-hundred day moving average of $13.23. The company has a market capitalization of $29.60 million, a price-to-earnings ratio of -0.96 and a beta of 0.41.

ImageneBio (NASDAQ:IMA) last issued its quarterly earnings data on Thursday, July 24th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.08. On average, equities analysts anticipate that ImageneBio will post -0.91 earnings per share for the current year.

Institutional Trading of ImageneBio

Hedge funds and other institutional investors have recently made changes to their positions in the stock. BML Capital Management LLC increased its stake in shares of ImageneBio by 3.5% in the first quarter. BML Capital Management LLC now owns 3,710,803 shares of the company’s stock worth $4,750,000 after buying an additional 124,937 shares during the last quarter. Goldman Sachs Group Inc. increased its stake in shares of ImageneBio by 62.4% in the first quarter. Goldman Sachs Group Inc. now owns 76,464 shares of the company’s stock worth $98,000 after buying an additional 29,369 shares during the last quarter. Aldebaran Capital LLC bought a new stake in shares of ImageneBio in the first quarter worth $317,000. Finally, XTX Topco Ltd increased its stake in shares of ImageneBio by 350.6% in the first quarter. XTX Topco Ltd now owns 56,452 shares of the company’s stock worth $72,000 after buying an additional 43,924 shares during the last quarter. Institutional investors own 75.00% of the company’s stock.

ImageneBio Company Profile

ImageneBio, Inc, a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc and changed its name to ImageneBio, Inc in July 2025.